All Outputs (3)

Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol (2023)
Journal Article
Date, K., Williams, B., Cohen, J., Chaudhuri, N., Bajwah, S., Pearson, M., …Johnson, M. (2023). Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol. ERJ Open Research, 9(4), Article 00167. https://doi.org/10.1183/23120541.00167-2023

Chronic breathlessness, a persistent and disabling symptom despite optimal treatment of underlying causes, is a frightening symptom with serious and widespread impact on patients and their carers. Clinical guidelines support the use of morphine for t... Read More about Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol.

Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial (2018)
Journal Article
Hutchinson, A., Rees, S., Young, A., Maraveyas, A., Date, K., & Johnson, M. J. (2019). Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. Palliative medicine, 33(5), 510-517. https://doi.org/10.1177/0269216318815377

Background: Cancer patients have a four- to fivefold greater risk of thrombosis than the general population. Recommended treatment for cancer-associated thrombosis is 3–6 months of low-molecular-weight heparin. The ‘select-d’ trial is an open-label,... Read More about Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.

Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer (2017)
Journal Article
Date, K., Ettelaie, C., & Maraveyas, A. (2017). Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer. Journal of thrombosis and haemostasis : JTH, 15(12), 2289-2299. https://doi.org/10.1111/jth.13871

© 2017 International Society on Thrombosis and Haemostasis Summary: Cancer is associated with an increased risk of venous thromboembolism (VTE); the exact mechanisms for the induction of VTE remain to be fully elucidated, but it is widely acknowledge... Read More about Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer.